Research into and identification of Mycobacterium tuberculosis can take on a number of facets, many of which involve the use of DNA at one stage or another. The quality and quantity of DNA required will depend on the end-use requirement. For example, good yields of pure, high-molecular-weight DNA uncontaminated by DNA from other sources (i.e., homogeneous) are optimal for the generation of cosm...

tuberculosis is one of the most common infectious diseases in the world. in recent years, genetically approach has been developed. one of the interesting gene for investigator is ifn-γr1. in this study we determind susceptibility to tuberculosis with polymorphism of ifn-γr1 gene. fifthly patients with smear positive tuberculosis have been chosen randomly. they were matched with 54 healthy contr...

” Niels Henrik Abel (august 5, 1802 april 6 , 1829) ... In 1822, he entered the University of Christiania [today’s Oslo] .. died at twenty-six of tubercolosis. His best known works are: the result that algebraic equations of order five or above cannot in general be solved algebraically; the result that *Abelian equations [I.e., with Abelian Galois group] can be solved algebraically; the theory ...

Endobronchial Tuberculosis (EBTB) is a particular form of TB non easily recognizable, often dangerous for its consequences and potentially a source of spread of infection in the community. Also its definition doesn't find a unanimity. In fact it has been defined as “tuberculous infection of the tracheo bronchial tree with microbial and histopathological evidence” [1] or a” complication of progr...

Mycobacterium tuberculosis FabH, an essential enzyme in the mycolic acid biosynthetic pathway, is an attractive target for novel anti-tubercolosis agents. Structure-based design and synthesis of 1-(4-carboxybutyl)-4-(4-(substituted benzyloxy)phenyl)-1H-pyrrole-2-carboxylic acid derivatives 7a-h, a subset of eight potential FabH inhibitors, is described in this paper. The Vilsmeier-Haack reactio...

Alemtuzumab is usually associated with opportunistic infections. We have treated 67 patients, 8 non-Hodgkin's lymphoma and 59 chronic lymphocytic leukemia (CLL) with campath. Among CLL patients, 6 used alemtuzumab in first line, alone or with chemotherapy, 41 as consolidation therapy and 11 as salvage therapy, 3 alone and 8 with chemotherapy. In our series opportunistic infections were prevalen...